Drug Trial Radar · NCT07700979
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Sep 24, 2026
Primary completion
Aug 18, 2029
Study completion Aug 18, 2030
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Jul 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.
Conditions
- Gastric / Gastroesophageal Junction Adenocarcinoma
Interventions
CadonilimabDrug
Anti-PD-1/ CTLA-4 tetrameric bispecific antibody
CAPOX regimenDrug
A combination treatment contains oxaliplatin and capecitabine
NivolumabDrug
Anti-PD-1 monoclonal antibody
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Approximately up to 14months
Locations
25 sites in 4 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona · Not yet recruiting
UCLA Health
Los Angeles, California · Not yet recruiting
Rocky Mountain Cancer Centers
Denver, Colorado · Not yet recruiting
Yale School of Medicine
New Haven, Connecticut · Not yet recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Not yet recruiting
Henry Ford Health
Detroit, Michigan · Not yet recruiting
Mount Sinai
New York, New York · Not yet recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Not yet recruiting
Oregon Health and Science University
Portland, Oregon · Not yet recruiting
Sarah Cannon Research Institute (SCRI) - Oncology Partners
Nashville, Tennessee · Not yet recruiting
Baylor Scott & White Health
Dallas, Texas · Not yet recruiting
MD Anderson Cancer Center
Houston, Texas · Not yet recruiting
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin · Not yet recruiting
Beijing Friendship Hospital, Capital Medical University
Beijing, China · Not yet recruiting
Peking University Cancer Hospital, Gastrointestinal Cancer Center I
Beijing, China · Recruiting
Peking University Cancer Hospital, Gastrointestinal Oncology
Beijing, China · Not yet recruiting
Guangdong Provincial People's Hospital
Guangzhou, China · Not yet recruiting
Zhongshan Hospital Fudan University
Shanghai, China · Not yet recruiting
University Cancer Center Frankfurt
Frankfurt, Germany · Not yet recruiting
Universitätsmedizin der Johannes Gutenberg-Universität
Mainz, Germany · Not yet recruiting
Univerity Marburg
Marburg, Germany · Not yet recruiting
Universitaetsklinikum Essen
Essen, North Rhine-Westphalia, Germany · Not yet recruiting
Pratia MCM Kraków
Krakow, Poland · Not yet recruiting
Pratia Poznań
Poznan, Poland · Not yet recruiting
Narodowy Instytut Onkologii-im. Marii Sklodowskiej Curie Panstwowy Instytut Badawczy - w Warszawie
Warsaw, Poland · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.